Four drugs added to Blue Cross of California formulary, including Schering-Plough's Claritin, Knoll's Dilaudid, SmithKline Beecham's Paxil and Janssen's Propulsid. Blue Cross' newsletter to pharmacies notes that Paxil "should be reserved for patients who cannot tolerate the side effects or who do not respond to the tricyclic antidepressants." Propulsid "should be reserved for patients who have failed or cannot tolerate metoclopramide." The pharmacy benefits company is adding a pharmacy incentive, paying pharmacies "an annual bonus of $0.20 on each generic prescription dispensed if [their] generic substitution rate surpasses 79.99% of the available multi-source medications." An additional annual bonus of $0.30 will be paid for each drug dispensed that is listed on the Blue Cross of California formulary if the pharmacy's formulary dispensing rate is greater than 84.99%, the company says
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth